Biocon launches insulin glargine in India
This article was originally published in Scrip
Biocon, an Indian biotechnology company, has launched its long-acting human insulin analogue, glargine (marketed as Basalog), a version of Sanofi Aventis' Lantus, on the domestic market. Basalog is available in 10ml and 3ml vials. Long-acting insulin analogues such as glargine are believed to facilitate better metabolic control and also slow the progression of the disease with fewer advanced diabetic complications such as retinopathy, neuropathy, nephropathy and cardiac complications like hypertension, myocardial infarction or stroke.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.